Dysregulation in keratinocytes drives systemic lupus erythematosus onset
- PMID: 39627610
- PMCID: PMC11686216
- DOI: 10.1038/s41423-024-01240-z
Dysregulation in keratinocytes drives systemic lupus erythematosus onset
Abstract
Systemic lupus erythematosus (SLE) is a complex, multiorgan autoimmune disorder. Although it is widely believed that SLE originates from immune cell dysregulation, the etiology of SLE is not yet clear. Here, we propose a new theory in which SLE can be directly initiated by molecular alterations in keratinocytes rather than immune cells. We found that the level of peroxisome proliferator-activated receptor gamma (PPARγ) is substantially reduced in the skin lesions of patients, and replicating this reduction in mice led to rapid disease onset with multiple hallmarks of SLE. As PPARγ decreases in keratinocytes, which is accompanied by increased occupancy of interferon regulatory factor 3 at the type I interferon locus, dendritic cells (DCs) are recruited to the epidermis and are activated by keratinocyte-secreted type I interferon. These activated DCs migrate to local draining lymph nodes, where they activate CD4+ T cells in a non-MHC II-dependent manner, promoting their differentiation into effector T cells and thus contributing to disease onset. Our study revealed that the dysregulation of keratinocytes can be a pathogenic driver of SLE and describes a new mouse model that mimics human SLE. Our data also emphasize the pivotal role of skin immunity in the onset of systemic autoimmune disease.
Keywords: Dendritic cells; Interferon regulatory factor 3; Keratinocytes; Peroxisome proliferator-activated receptor gamma; Systemic lupus erythematosus; Type I interferon.
© 2024. The Author(s), under exclusive licence to CSI and USTC.
Conflict of interest statement
Competing interests: The authors declare that they have no competing interests. QL and DY are editorial board members of Cellular & Molecular Immunology, but they have not been involved in the peer review or the decision-making of the article.
Similar articles
-
Induction of Type I Interferon-Dependent Activation and Migration of Inflammatory Dendritic Cells to Local Lymph Nodes by UV Light Exposure.Arthritis Rheumatol. 2025 Jul;77(7):867-875. doi: 10.1002/art.43108. Epub 2025 Feb 7. Arthritis Rheumatol. 2025. PMID: 39800946
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Lupus IgA1 autoantibodies synergize with IgG to enhance plasmacytoid dendritic cell responses to RNA-containing immune complexes.Sci Transl Med. 2024 Jul 3;16(754):eadl3848. doi: 10.1126/scitranslmed.adl3848. Epub 2024 Jul 3. Sci Transl Med. 2024. PMID: 38959329 Free PMC article.
-
Maternal and neonatal outcomes of elective induction of labor.Evid Rep Technol Assess (Full Rep). 2009 Mar;(176):1-257. Evid Rep Technol Assess (Full Rep). 2009. PMID: 19408970 Free PMC article.
-
Association between Type I interferon and depletion and dysfunction of endothelial progenitor cells in C57BL/6 mice deficient in both apolipoprotein E and Fas ligand.Curr Res Transl Med. 2018 Sep;66(3):71-82. doi: 10.1016/j.retram.2018.02.002. Epub 2018 Aug 11. Curr Res Transl Med. 2018. PMID: 30108025 Free PMC article.
Cited by
-
Increasing evidence for the pathogenic role of keratinocytes in lupus.Cell Mol Immunol. 2025 Mar;22(3):333-335. doi: 10.1038/s41423-024-01254-7. Epub 2025 Jan 17. Cell Mol Immunol. 2025. PMID: 39825106 No abstract available.
-
New Mechanisms and Therapeutic Targets in Systemic Lupus Erythematosus.MedComm (2020). 2025 Jun 9;6(6):e70246. doi: 10.1002/mco2.70246. eCollection 2025 Jun. MedComm (2020). 2025. PMID: 40491969 Free PMC article. Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials